Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
317
Views
49
CrossRef citations to date
0
Altmetric
Review

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

Veena Mathew1 Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA, [email protected]
&
Annabel K Wang1 Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA, [email protected];2 Neurology Section, Tibor Rubin VA Medical Center, Long Beach, CA, USA, [email protected]Correspondence[email protected]
Pages 1515-1525 | Published online: 06 May 2019

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Naim Alkhouri & Samer Gawrieh. (2021) A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opinion on Investigational Drugs 30:3, pages 237-244.
Read now
Xiaohua Guo, Zhaowen Liu, Yizhou Zheng, Yamei Li, Linfu Li, Hai Liu, Zhixi Chen & Longhuo Wu. (2020) Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors. Drug Design, Development and Therapy 14, pages 1057-1081.
Read now
Adrián M. Ramos, Beatriz Fernández-Fernández, María Vanessa Pérez-Gómez, Sol María Carriazo Julio, María Dolores Sanchez-Niño, Ana Sanz, Marta Ruiz-Ortega & Alberto Ortiz. (2020) Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opinion on Drug Discovery 15:1, pages 101-115.
Read now

Articles from other publishers (46)

Benedikt Kaufmann, Marta de Los Reyes Jiménez, Laela M. Booshehri, Janset Onyuru, Aleksandra Leszczynska, Anna Uri, Sven Michel, Richard Klar, Frank Jaschinski, Ariel E. Feldstein, Lori Broderick & Hal M. Hoffman. (2023) Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice . The Journal of Immunology 211:2, pages 287-294.
Crossref
Jan L. De Bleecker, Kristl G. Claeys, Stéphanie Delstanche, Vinciane Van Parys, Jonathan Baets, Sébastien Tilleux & Gauthier Remiche. (2023) A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium. Acta Neurologica Belgica 123:3, pages 1029-1037.
Crossref
Daniele Severi, Giovanni Palumbo, Emanuele Spina, Aniello Iovino, Maria Nolano, Fiore Manganelli & Stefano Tozza. (2022) A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment. Neurological Sciences 44:4, pages 1419-1422.
Crossref
Ariana Araya, David Arias, Karla Coto, María Rebeca López, Joselyn Rivera & Juan José Mora. (2023) Antisense Oligonucleotides: Concepts and Pharmaceutical Applications. Borneo Journal of Pharmacy 6:1, pages 41-57.
Crossref
Christopher Robinson, Cynthia Pham, Alec M. Zamarripa, Chase S. Dugay, Christopher A. Lee, Amnon A. Berger, Avi Landman, Elyse M. Cornett, Hisham Kassem, Alan D. Kaye, Ivan Urits, Omar Viswanath & Latha Ganti. (2023) Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis. Health Psychology Research 10:5.
Crossref
Theofanis Vavilis, Eleni Stamoula, Alexandra Ainatzoglou, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas & Ioannis S. Vizirianakis. (2023) mRNA in the Context of Protein Replacement Therapy. Pharmaceutics 15:1, pages 166.
Crossref
Satheesh Kumar, Lewis E. Fry, Jiang-Hui Wang, Keith R. Martin, Alex W. Hewitt, Fred K. Chen & Guei-Sheung Liu. (2023) RNA-targeting strategies as a platform for ocular gene therapy. Progress in Retinal and Eye Research 92, pages 101110.
Crossref
Fabio Mastrocola, Frank Nunes & Paulo Sgobbi. 2023. Amyloidosis and Fabry Disease. Amyloidosis and Fabry Disease 235 276 .
Lisseth Estefania Burbano, Melody Li, Nikola Jancovski, Paymaan Jafar-Nejad, Kay Richards, Alicia Sedo, Armand Soriano, Ben Rollo, Linghan Jia, Elena V. Gazina, Sandra Piltz, Fatwa Adikusuma, Paul Q. Thomas, Helen Kopsidas, Frank Rigo, Christopher A. Reid, Snezana Maljevic & Steven Petrou. (2022) Antisense oligonucleotide therapy for KCNT1 encephalopathy. JCI Insight 7:23.
Crossref
Thomas H. Brannagan3rd3rd, John L. Berk, Julian D. Gillmore, Mathew S. Maurer, Márcia Waddington‐Cruz, Marianna Fontana, Ahmad Masri, Laura Obici, Michela Brambatti, Brenda F. Baker, Lisa A. Hannan, Gustavo Buchele, Nick J. Viney, Teresa Coelho & Jose Nativi‐Nicolau. (2022) Liver‐directed drugs for t ransthyretin‐mediated amyloidosis . Journal of the Peripheral Nervous System 27:4, pages 228-237.
Crossref
Hangyu Wu, Aniket Wahane, Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, SooWan Lee, Evan M. McCabe, Theodore P. Rasmussen, Raman Bahal, Xiao-bo Zhong & José E. Manautou. (2022) Nephrotoxicity of marketed antisense oligonucleotide drugs. Current Opinion in Toxicology 32, pages 100373.
Crossref
Shikha Thakur, Apurba Sinhari, Priti Jain & Hemant R. Jadhav. (2022) A perspective on oligonucleotide therapy: Approaches to patient customization. Frontiers in Pharmacology 13.
Crossref
Yongshu Li, Bihui Huang, Zhichao Xue, Yunhua Gao & Zhenjian Zhuo. (2022) Nucleic acid therapy in pediatric cancer. Pharmacological Research 184, pages 106441.
Crossref
David C. Swinney. (2022) Why medicines work. Pharmacology & Therapeutics 238, pages 108175.
Crossref
Chafic Karam, Duncan Brown, Min Yang, Nicolae Done, Jing Jing Zhu, Alexandra Greatsinger, Ana Bozas, Montserrat Vera‐Llonch & James Signorovitch. (2022) Long‐term treatment effects of inotersen on health‐related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open‐label extension of the NEURO‐TTR trial . Muscle & Nerve 66:4, pages 438-446.
Crossref
Chafic Karam, Duncan Brown, Min Yang, Nicolae Done, Ibou Dieye, Ana Bozas, Montserrat Vera Llonch & James Signorovitch. (2022) Factors associated with increased health‐related quality‐of‐life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen . Muscle & Nerve 66:3, pages 319-328.
Crossref
Miklós Bege & Anikó Borbás. (2022) The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. Pharmaceuticals 15:8, pages 909.
Crossref
Joseph O'Sullivan, Jose Muñoz-Muñoz, Graeme Turnbull, Neil Sim, Stuart Penny & Sterghios Moschos. (2022) Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics. RSC Advances 12:32, pages 20432-20446.
Crossref
Joana Silva & Paula A. da Costa Martins. (2022) Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy. Cells 11:11, pages 1805.
Crossref
Mariella Bockstahler, Christian Salbach, Anna‐Maria Müller, Andrea Kübler, Oliver J. Müller, Hugo A. Katus, Norbert Frey & Ziya Kaya. (2021) LNA oligonucleotide mediates an anti‐inflammatory effect in autoimmune myocarditis via targeting lactate dehydrogenase B. Immunology 165:2, pages 158-170.
Crossref
Dhaval Oza & Mansoor M. Amiji. 2022. Macrophage Targeted Delivery Systems. Macrophage Targeted Delivery Systems 357 378 .
Maike F. Dohrn, Jessica Medina, Karmele R. Olaciregui Dague & Ernst Hund. (2021) Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurological Research and Practice 3:1.
Crossref
Akash Gupta, Jason L. Andresen, Rajith S. Manan & Robert Langer. (2021) Nucleic acid delivery for therapeutic applications. Advanced Drug Delivery Reviews 178, pages 113834.
Crossref
Manish Pandey, Divya Ojha, Sakshi Bansal, Ambadas B. Rode & Geetanjali Chawla. (2021) From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine 81, pages 101003.
Crossref
Shipra Malik, W. Mark Saltzman & Raman Bahal. (2021) Extracellular vesicles mediated exocytosis of antisense peptide nucleic acids. Molecular Therapy - Nucleic Acids 25, pages 302-315.
Crossref
Ya Ying Zheng, Ying Wu, Thomas J. Begley & Jia Sheng. (2021) Sulfur modification in natural RNA and therapeutic oligonucleotides. RSC Chemical Biology 2:4, pages 990-1003.
Crossref
Christopher L. Cioffi, Arun Raja, Parthasarathy Muthuraman, Aravindan Jayaraman, Srinivasan Jayakumar, Andras Varadi, Boglarka Racz & Konstantin Petrukhin. (2021) Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities. Journal of Medicinal Chemistry 64:13, pages 9010-9041.
Crossref
James Michael Sutton, Jaeah Kim, Noha M. El Zahar & Michael G. Bartlett. (2020) BIOANALYSIS AND BIOTRANSFORMATION OF OLIGONUCLEOTIDE THERAPEUTICS BY LIQUID CHROMATOGRAPHY‐MASS SPECTROMETRY. Mass Spectrometry Reviews 40:4, pages 334-358.
Crossref
Teresa Coelho, Yukio Ando, Merrill D. Benson, John L. Berk, Márcia Waddington-Cruz, Peter J. Dyck, Julian D. Gillmore, Sami L. Khella, William J. Litchy, Laura Obici, Cecilia Monteiro, Li-Jung Tai, Nicholas J. Viney, Gustavo Buchele, Michela Brambatti, Shiangtung W. Jung, Louis St. L. O’Dea, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Brett P. Monia & Morie Gertz. (2021) Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy 10:1, pages 375-389.
Crossref
Maria Gagliardi & Ana Tari Ashizawa. (2021) The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. Biomedicines 9:4, pages 433.
Crossref
Suzan M Hammond, Annemieke Aartsma‐Rus, Sandra Alves, Sven E Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela A Denti, Lourdes R Desviat, Lucía Echevarría, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T Goyenvalle, Magdalena Guzowska, Irina Holodnuka, David R Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke Van Roon‐Mom & Virginia Arechavala‐Gomeza. (2021) Delivery of oligonucleotide‐based therapeutics: challenges and opportunities. EMBO Molecular Medicine 13:4.
Crossref
Naim Alkhouri, G. Kesava Reddy & Eric Lawitz. (2021) Oligonucleotide‐Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology 73:4, pages 1581-1593.
Crossref
Tulsi Ram Damase, Roman Sukhovershin, Christian Boada, Francesca Taraballi, Roderic I. Pettigrew & John P. Cooke. (2021) The Limitless Future of RNA Therapeutics. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Zhili Tian, Guohui Liang, Kunli Cui, Yayu Liang, Qun Wang, Shuangyu Lv, Xiaoxia Cheng & Lei Zhang. (2021) Insight Into the Prospects for RNAi Therapy of Cancer. Frontiers in Pharmacology 12.
Crossref
Martina H. Lundberg Slingsby, Prakrith Vijey, I-Ting Tsai, Harvey Roweth, Genevieve Couldwell, Adrian R. Wilkie, Hans Gaus, Jazana M. Goolsby, Ross Okazaki, Brooke E. Terkovich, John W. Semple, Jonathan N. Thon, Scott P. Henry, Padmakumar Narayanan & Joseph E. Italiano Jr.. (2021) Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates. Haematologica 107:2, pages 519-531.
Crossref
Jamie V. Shiah, Jennifer R. Grandis & Daniel E. Johnson. (2021) Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. Molecular Cancer Therapeutics 20:2, pages 219-228.
Crossref
Takeshi Yokoyama & Mineyuki Mizuguchi. (2020) Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments. Journal of Medicinal Chemistry 63:23, pages 14228-14242.
Crossref
Ana Frangolho, Bruno E. Correia, Daniela C. Vaz, Zaida L. Almeida & Rui M. M. Brito. (2020) Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity. Molecules 25:23, pages 5698.
Crossref
Tomoki Kobayashi, Keishi Kanno, Phuong Thao Nguyen, Akiko Sugiyama, Akihiro Kawahara, Yuichiro Otani, Nobusuke Kishikawa, Masanori Ito & Susumu Tazuma. (2020) Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non‐alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 35:12, pages 2140-2150.
Crossref
Eric Valeur. 2020. Protein Degradation with New Chemical Modalities. Protein Degradation with New Chemical Modalities 277 316 .
E. Srinivasan, Nandhini Natarajan & R. Rajasekaran. (2020) TTRMDB: A database for structural and functional analysis on the impact of SNPs over transthyretin (TTR) using bioinformatic tools. Computational Biology and Chemistry 87, pages 107290.
Crossref
Alex Dworetz, Christina Graley, Hiral Padia & Kelly G. Gwathmey. (2020) Neurologic Manifestations of Systemic Disease: Peripheral Nervous System. Current Treatment Options in Neurology 22:8.
Crossref
Marc Suñé-Pou, María J. Limeres, Cristina Moreno-Castro, Cristina Hernández-Munain, Josep M. Suñé-Negre, María L. Cuestas & Carlos Suñé. (2020) Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease. Frontiers in Genetics 11.
Crossref
Aniket Wahane, Akaash Waghmode, Alexander Kapphahn, Karishma Dhuri, Anisha Gupta & Raman Bahal. (2020) Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy. Molecules 25:12, pages 2866.
Crossref
Maria Mahfouz, Rika Maruyama & Toshifumi Yokota. 2020. Gapmers. Gapmers 87 98 .
Leanna Chan & Toshifumi Yokota. 2020. Gapmers. Gapmers 21 47 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.